From this new laboratory suite, Catalent will offer expert analytical testing, development support and regulatory services to pharmaceutical and biopharmaceutical companies. The laboratory suite incorporates expanded, state-of-the-art facilities for the storage and testing of controlled and cytotoxic substances.
Catalent's new Swindon laboratories offer a comprehensive range of development and analytical services. These services include European importtesting, Qualified Person (QP) and regulatory consulting services, methods development, and microbial, sterility and stability testing for a range of advanced dose forms including for inhaled and orally administered substances.
“This additional capacity, coupled with our international network, means Catalent can offer an unparalleled range and scale of services to the development and testing of large and small molecules,” commented Graeme Lowe, Director of Analytical Solutions for Catalent in Swindon.
“The enhanced facilitieshere in Swindon are complimented by Catalent's acquisitions of Aptuit's Clinical Trials Supply business and the full ownership of the Eberbach softgel facility. We are now offering a broader range of pharmaceutical and biopharmaceutical testing services fromfive locations in the US, UK and Germany. We have the expertise and the global reach to help our customers bring more products to market faster,” said Christine Dolan, Vice President and General Manager of Catalent's Development and Analytical Solutions.
Catalent's new Swindon laboratories offer a comprehensive range of development and analytical services. These services include European importtesting, Qualified Person (QP) and regulatory consulting services, methods development, and microbial, sterility and stability testing for a range of advanced dose forms including for inhaled and orally administered substances.
“This additional capacity, coupled with our international network, means Catalent can offer an unparalleled range and scale of services to the development and testing of large and small molecules,” commented Graeme Lowe, Director of Analytical Solutions for Catalent in Swindon.
“The enhanced facilitieshere in Swindon are complimented by Catalent's acquisitions of Aptuit's Clinical Trials Supply business and the full ownership of the Eberbach softgel facility. We are now offering a broader range of pharmaceutical and biopharmaceutical testing services fromfive locations in the US, UK and Germany. We have the expertise and the global reach to help our customers bring more products to market faster,” said Christine Dolan, Vice President and General Manager of Catalent's Development and Analytical Solutions.
Companies in this article
![“Another key [UDI] benefit, because we're calling that product by the same name across the healthcare supply chain… rich and robust data that we can access around supply consumption and utilization rates. One of the buzz terms we've heard during the COVID-19 crisis was what's my burn rate? How fast am I going through gowns, masks, gloves?” – Mike Schiller, Senior Director at AHRMM](https://img.healthcarepackaging.com/files/base/pmmi/all/image/2020/08/UDI.5f4d326e41d53.png?auto=format&fit=crop&h=146&w=340)
